Inhibition of the histone methyltransferase EZH2 induces vascular stiffness

被引:4
作者
Ibarrola, Jaime [1 ]
Xiang, Rachel R. [1 ]
Sun, Zhe [2 ]
Lu, Qing [1 ]
Hill, Michael A. [2 ]
Jaffe, Iris Z. [1 ]
机构
[1] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA
[2] Univ Missouri, Dalton Cardiovasc Res Ctr, Dept Med Pharmacol & Physiol, Columbia, MO 65203 USA
基金
美国国家卫生研究院;
关键词
SMOOTH-MUSCLE-CELL; MATRIX METALLOPROTEINASES; NUCLEAR ACTIN; EPIGENETICS; HYPERTENSION; MECHANISMS; PHENOTYPE; DISEASE;
D O I
10.1042/CS20231478
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Vascular stiffness increases with aging, obesity and hypertension and predicts cardiovascular risk. The levels of histone H3-lysine-27 methylation (H3K27me) and the histone methyltransferase EZH2 both decrease in aging vessels, driving vascular stiffness. The impact of EZH2 inhibitors on vascular stiffness is unknown. We tested the hypothesis that the EZH2 inhibitor GSK126, currently in development for cancer treatment, increases vascular stiffness and explored underlying molecular mechanisms. Young (3 month) and middle-aged (12 month) male mice were treated with GSK126 for 1-2 months and primary human aortic smooth muscle cells (HASMCs) from young male and female donors were treated with GSK126 for 24-48 h. Stiffness was measured in vivo by pulse wave velocity and in vitro by atomic force microscopy (AFM) and vascular structure was quantified histologically. Extracellular matrix proteins were studied by qRT-PCR, immunoblotting, zymography and chromatin immunoprecipitation. GSK126 treatment decreased H3K27 methylation (H3K27me) and increased acetylation (H3K27ac) in mouse vessels and in HASMCs. In GSK126-treated mice, aortic stiffness increased without changes in vascular fibrosis. EZH2 inhibition enhanced elastin fiber degradation and matrix metalloprotease-2 (MMP2) expression. In HASMCs, GSK126 treatment increased synthetic phenotype markers and intrinsic HASMCs stiffness by AFM with altered cytoskeletal structure and increased nuclear actin staining. GSK126 also increased MMP2 protein expression, activity and enrichment of H3K27ac at the MMP2 promoter in HASMCs. GSK126 causes vascular stiffening, inducing MMP2 activity, elastin degradation, and modulation of SMC phenotype and cytoskeletal stiffness. These findings suggest that EZH2 inhibitors used to treat cancer could negatively impact the vasculature by enhancing stiffness and merits examination in human trials.
引用
收藏
页码:251 / 268
页数:18
相关论文
共 50 条
  • [41] Review: Targeting EZH2 in neuroblastoma
    Gao, Jinhui
    Fosbrook, Claire
    Gibson, Jane
    Underwood, Timothy J.
    Gray, Juliet C.
    Walters, Zoe S.
    [J]. CANCER TREATMENT REVIEWS, 2023, 119
  • [42] EZH2: An Accomplice of Gastric Cancer
    Yu, Wuhan
    Liu, Ning
    Song, Xiaogang
    Chen, Lang
    Wang, Mancai
    Xiao, Guohui
    Li, Tengfei
    Wang, Zheyuan
    Zhang, Youcheng
    [J]. CANCERS, 2023, 15 (02)
  • [43] Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2
    Dudakovic, Amel
    Samsonraj, Rebekah M.
    Paradise, Christopher R.
    Galeano-Garces, Catalina
    Mol, Merel O.
    Galeano-Garces, Daniela
    Zan, Pengfei
    Galvan, M. Lizeth
    Hevesi, Mario
    Pichurin, Oksana
    Thaler, Roman
    Begun, Dana L.
    Kloen, Peter
    Karperien, Marcel
    Larson, A. Noelle
    Westendorf, Jennifer J.
    Cool, Simon M.
    van Wijnen, Andre J.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (23) : 7877 - 7893
  • [44] EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
    Katona, Bryson W.
    Liu, Yuanyuan
    Ma, Anqi
    Jin, Jian
    Hua, Xianxin
    [J]. CANCER BIOLOGY & THERAPY, 2014, 15 (12) : 1677 - 1687
  • [45] EZH2 is highly expressed in pituitary adenomas and associated with proliferation
    Schult, David
    Hoelsken, Annett
    Siegel, Sonja
    Buchfelder, Michael
    Fahlbusch, Rudolf
    Kreitschmann-Andermahr, Ilonka
    Buslei, Rolf
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [46] Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression
    Grzenda, Adrienne
    Lomberk, Gwen
    Svingen, Phyllis
    Mathison, Angela
    Calvo, Ezequiel
    Iovanna, Juan
    Xiong, Yuning
    Faubion, William
    Urrutia, Raul
    [J]. EPIGENETICS & CHROMATIN, 2013, 6
  • [47] Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression
    Adrienne Grzenda
    Gwen Lomberk
    Phyllis Svingen
    Angela Mathison
    Ezequiel Calvo
    Juan Iovanna
    Yuning Xiong
    William Faubion
    Raul Urrutia
    [J]. Epigenetics & Chromatin, 6
  • [48] EZH2 as a Potential Target for NAFLD Therapy
    Lim, Hyun Jung
    Kim, Mirang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 15
  • [49] Emerging EZH2 Inhibitors and Their Application in Lymphoma
    Jennifer K. Lue
    Jennifer E. Amengual
    [J]. Current Hematologic Malignancy Reports, 2018, 13 : 369 - 382
  • [50] Emerging EZH2 Inhibitors and Their Application in Lymphoma
    Lue, Jennifer K.
    Amengual, Jennifer E.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (05) : 369 - 382